Response criteria for intraocular retinoblastoma: RB-RECIST.

Journal Article (Journal Article)

Standardized guidelines for assessing tumor response to therapy are essential for designing and conducting clinical trials. The Response Evaluation Criteria In Solid Tumors (RECIST) provide radiological standards for assessment of solid tumors. However, no such guidelines exist for the evaluation of intraocular cancer, and ocular oncology clinical trials have largely relied on indirect measures of therapeutic response-such as progression-free survival-to evaluate the efficacy of treatment agents. Herein, we propose specific criteria for evaluating treatment response of retinoblastoma, the most common pediatric intraocular cancer, and emphasize a multimodal imaging approach for comprehensive assessment of retinoblastoma tumors in clinical trials.

Full Text

Duke Authors

Cited Authors

  • Berry, JL; Munier, FL; Gallie, BL; Polski, A; Shah, S; Shields, CL; Gombos, DS; Ruchalski, K; Stathopoulos, C; Shah, R; Jubran, R; Kim, JW; Mruthyunjaya, P; Marr, BP; Wilson, MW; Brennan, RC; Chantada, GL; Chintagumpala, MM; Murphree, AL

Published Date

  • May 1, 2021

Published In

Volume / Issue

  • 68 / 5

Start / End Page

  • e28964 -

PubMed ID

  • 33624399

Pubmed Central ID

  • PMC8049511

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

Digital Object Identifier (DOI)

  • 10.1002/pbc.28964


  • eng

Conference Location

  • United States